Astrazeneca Pharma India Ltd Share Price (ASTRAZEN)

AstraZeneca Pharma India Limited (APIL) was incorporated on the 11th of July 1979 and is a subsidiary of AstraZeneca Pharmaceuticals AB Sweden, which is an indirect subsidiary of AstraZeneca Plc. It is engaged in manufacture, distribution and marketing of pharmaceutical products in therapy areas such as Onocology, Alimentary Metabolism, Cardio Vascular, Renal Diabetes, Respiratory and Oncology. The company suffered a performance setback due to supply stabilization in 2012, following which the current year witnessed series of regulatory interventions in the Indian Pharmaceutical Market covering 348 medicines including 15 SKUs across 8 brands of the company listed on the National List of Essential Medicines (NLEM). During the year, APIL introduced Arimidex, an Oncology product for the management of breast cancer and decided to make its Astrazeneca India’s RD as a part of its global RD organisation. In 2013-14, the market share of drug brand Brilinta (Ticagrelor) which provides cardiologists with a new and effective treatment to help reduce the rate of heart attack and cardiovascular deaths grew from 1.4 MAT March 2013 to 6.7 MAT March 2014. For the FY 2013-14, the company experienced a range of patient price reduction of 452 and an average price reduction of 30. In 2015-16, key growth brands of APIL such as Brilinta, Forxiga, Onglyza, Kombiglyze, Symbicort witnessed robust growth and diabetes portfolio grew by 74 post acquisition from Bristol MyersSquibb. Meanwhile, Meronem became the company’s first brand to cross the Rs. 100 crore sales milestone. The company entered into three Distribution Services Agreements with Dr. Reddy's Laboratories, Sun Pharma for Ticagrelor and Diabetes treatments, while APIL, Dr. Reddy's Laboratories and Sun Pharma copromote market and distributed Saxagliptin, Dapagliflozin and Ticagrelor under different brand names in Indian markets. During 2017-18, the company aligned its portfolio to AstraZeneca's Global therapeutic focus and introduced Xigduo, a fixed dose combination drug to improve glycemic control for type 2 diabetes mellitus. In 2020-21, the company launched Lynparza, Calquence Acalabrutinib and Benralizumab

Revenue: ₹480.48Cr as on March 2025 (Q4 FY25)
Net Profit: ₹58.25Cr as on March 2025 (Q4 FY25)
Listing date: 30 Jul, 1998
Chairperson Name: Narayan K Seshadri